Objective: To review clinical data regarding the newly approved drug setmelanotide, an injectable melanocortin 4 receptor (MC4R) agonist, for chronic weight management in adults and children aged 6 years and older with monogenic obesity. Data Sources: A literature review was performed by searching MEDLINE, SCOPUS, and EMBASE for all relevant English-language articles published between January 1, 1996, and November 30, 2021, using search terms obesity, setmelanotide, Imcivree, and MC4R agonist. Study Selection/Data Extraction: This review included two phase 2, two phase 3, and one ongoing clinical trial evaluating the efficacy and/or safety of setmelanotide. Data Synthesis: Setmelanotide demonstrates statistically significant weight loss with at least a 10% decrease in body weight after 1 year and decreased appetite in phase 2 and phase 3 clinical trials. The most common adverse effects included injection site reaction (96%), skin hyperpigmentation (78%), nausea (56%), headache (41%), and diarrhea (37%). Place in Therapy: Setmelanotide is the first and only Food and Drug Administration–approved medication for the treatment of proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, and leptin receptor deficiency in patients with obesity. It may be used in children and adults who have received genetic testing and exhibited extreme obesity before age five. Setmelanotide is a daily subcutaneous injection and may be difficult to afford for patients. Conclusion: Setmelanotide is an effective treatment in patients with obesity and indicated genetic disorders.
AyersKLGlicksbergBSGarfieldAS, et al. Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 2018;103(7):2601-2612. doi:10.1210/jc.2018-00258.
2.
MillingtonGW.The role of proopiomelanocortin (POMC) neurones in feeding behaviour. Nutr Metab. 2007;4(1):18. doi:10.1186/1743-7075-4-18
3.
LarsenLHEchwaldSMSørensenTI, et al. Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metab. 2005;90(1):219-224. doi:10.1210/jc.2004-0497.
4.
NordangGBNBuskØLTvetenK, et al. Next-generation sequencing of the monogenic obesity genes LEP, LEPR, MC4R, PCSK1 and POMC in a Norwegian cohort of patients with morbid obesity and normal weight controls. Mol Genet Metab. 2017;121(1):51-56. doi:10.1016/j.ymgme.2017.03.007.
5.
FarooqiISYeoGSKeoghJM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest. 2000;106(2):271-279. doi:10.1172/JCI9397.
6.
StyneDMArslanianSAConnorEL, et al. Pediatric obesity—assessment, treatment, and prevention: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709-757. doi:10.1210/jc.2016-2573.
MastrandreaLDWittenLCarlsson PetriKC, et al. Liraglutide effects in a pediatric (7-11 y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatr Obes. 2019;14(5):e12495. doi:10.1111/ijpo.12495.
9.
KellyASAuerbachPBarrientos-PerezM, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117-2128. doi:10.1056/NEJMoa1916038.
10.
ApovianCMAronneLJBessesenDH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2015;100(5):2135-2136]. J Clin Endocrinol Metab. 2015;100(2):342-362. doi:10.1210/jc.2014-3415.
11.
PoitouCPuderLDubernB, et al. Long-term outcomes of bariatric surgery in patients with bi-allelic mutations in the POMC, LEPR, and MC4R genes. Surg Obes Relat Dis. 2021;17(8):1449-1456. doi:10.1016/j.soard.2021.04.020.
ClémentKvan den AkkerEArgenteJ, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960-970. doi:10.1016/S2213-8587(20)30364-8.
14.
KühnenPClémentKWiegandS, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240-246. doi:10.1056/NEJMoa1512693.
15.
ClémentKBiebermannHFarooqiIS, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551-555. doi:10.1038/s41591-018-0015-9.
16.
Rhythm Pharmaceuticals. An open label, 1-year trial, including a double-blind placebo-controlled withdrawal period, of setmelanotide (RM-493), a melanocortin 4 receptor (MC4R) agonist, in early onset leptin receptor (LEPR) deficiency obesity due to bi-allelic loss-of-function LEPR genetic mutation. Published 2021. Accessed June 29, 2022. https://clinicaltrials.gov/ct2/show/NCT03287960.
17.
Rhythm Pharmaceuticals. An open label, 1-year trial, including a double-blind placebo-controlled withdrawal period, of RM-493, a MC4R agonist, in early onset POMC deficiency obesity due to bi-allelic loss-of-function POMC or PCSK1 genetic mutation. Published 2021. Accessed July 21, 2022. https://clinicaltrials.gov/ct2/show/study/NCT02896192.
18.
HawsRMGordonGHanJC, et al. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: phase 3 trial design. Contemp Clin Trials Commun. 2021;22:100780. doi:10.1016/j.conctc.2021.100780.
19.
NgMCBowdenDW.Is genetic testing of value in predicting and treating obesity. N C Med J. 2013;74(6):530-533. doi:10.18043/ncm.74.6.530.
20.
ApovianCMAronneLJBessesenDH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. doi:10.1210/jc.2014-3415.
LepsenEWZhangJThomsenHS, et al. Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. Cell Metab. 2018;28(1):23-32.e3.
